| Autor: |
Nizhevich AA, Akhmadeeva ÈN, Sataev VU, Bilalov FS |
| Jazyk: |
ruština |
| Zdroj: |
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology [Eksp Klin Gastroenterol] 2013 (5), pp. 23-6. |
| Abstrakt: |
Efficacy of sequential eradication therapy for H. pylori was studied in 176 adolescents (mean age 14.3 years) with different PPI metabolism types. Group I consisted from the patients received omeprazole as PPI in combined treatment with amoxycilline, clarithromycine and tinidazole, Group II--patients treated with rabeprazole in the combination with the same antibacterial drugs. In all the patients, CYP2C19 genotype was identified as a control rate of PPI metabolism (extensive, intermediate and poor metabolizers). Sequential therapy in the children with intermediate and poor metabolic activity demonstrated a high eradication rate irrespective of PPI type (> 80%). In the patients with extensive metabolism taking omeprazole, eradication standard turned out to be lower (63.4%) than in the rabeprazole group (82.3%) (p = 0.026). Results of our survey confirmed a potential advantage of rabeprazole-based treatment compared with omeprazole-containing regimen in the sequential treatment of H. pylori infection in childhood. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
